Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Neuroprotection with amifostine from platinum/taxane-based chemotherapy requires further study
December 1st, 2005
Scientists propose studying further the neuroprotective effects amifostine has on platinum/taxane-based chemotherapy. "Neurotoxicity is a common side effect of platinum/taxane-based therapy of ovarian cancer. We performed a double-blind randomized placebo-controlled trial to evaluate the influence of the cytoprotectant amifostine on the neurotoxicity of first-line therapy of ovarian cancer with paclitaxel/carboplatin with or without epirubicin," scientists in Germany reported. "Of 72 patients randomized, 71 were treated with paclitaxel 175 mg/m2 and carboplatin AUC5 with or without epirubicin 60 mg/m2 (q21x6) and randomized for...
Source: Women's Health Weekly (2005-12-01)
|
